Frost & Sullivan: iRegene Therapeutics Honored as "2025 Forbes China Leading Enterprises in Industry Development"
Amid the global trend of industrial innovation, the results of the "2025 Pioneer Innovators in Industry Development" selection jointly initiated by Forbes China and Frost & Sullivan were officially announced. iRegene Therapeutics was honored as one of Forbes China's 2025 Leading Enterprises in Industry Development. iRegene is pioneering the future of regenerative medicine with its AI-powered, chemically induced cell therapy platform. By combining cutting-edge technology, a robust R&D ecosystem, and a globally experienced leadership team, iRegene is redefining allogeneic therapies to make them safer, more effective, and broadly accessible. This recognition highlights iRegene's continued leadership in innovation and its commitment to transforming patient care through next-generation regenerative therapies.
iRegene Therapeutics Honored as 2025 Forbes China Leading Enterprises in Industry Development
Aroop Zutshi, Global Managing Partner and Executive Board Director of Frost & Sullivan, and Junyi Guo, General Manager of Business Operations at Forbes China, jointly presented the 2025 Forbes China Leading Enterprises in Industry Development award. Dr. Jun Wei, Chairman of iRegene Therapeutics, was invited to attend the gala.
AI-Driven Chemical-Induced Cell Therapy: Reshaping the Future of Accessible Cell Therapy
Since its establishment in 2017, iRegene Therapeutics has remained committed to addressing unmet clinical needs through the development of next-generation cell therapies. With a focus on chemically induced, universal cell therapy products, iRegene aims to deliver transformative treatments for patients with currently incurable diseases.
iRegene Therapeutics has a proprietary, AI-based platform for screening chemical compounds to modify specific cellular functions. The platform leverages induced pluripotent stem cells (iPSCs) to enhance treatment potential. By combining compounds to form a chemically induced culture medium, the "AI+Chem" platform can efficiently and precisely reprogram or optimize a cell's fate and function, thereby enhancing the clinical capabilities of cell therapies.
With a focus on the chemical induction system, iRegene has developed a comprehensive research and development (R&D) ecosystem and an international patent system that spans the industry. This ecosystem combines the discovery of 'cell fate determinants', the screening of chemical inducers and the validation of cellular function. The system does not use viral vector construction or transgenic methods; the straightforward CMC procedure is cost-efficient. Furthermore, cell transformation and functional optimization are entirely driven by the cells' natural genetic makeup. Transformation is synchronous under chemically enhanced regulation, eliminating the risk of genetic modification. iRegene's pioneering platform has been proven through the positive outcomes of the Phase I clinical trial.
In addition, iRegene's executive team has an international perspective, with all members having successful overseas experience in their specialized fields. CEO Dr Wei Jun is a leading expert in regenerative medicine and the induced pluripotent stem cell (iPSC) technology, bringing strategic leadership to the company. Chief Medical Officer Dr Cai Meng has extensive experience taking innovative therapies from discovery through clinical development, while Chief Quality Officer Ren Xiang is a senior regulatory expert who provides solid support from IND approval to NDA clearance in China, the US, and other countries. Executive Vice President Emmanuel Montet, formerly Vice President of the Asia-Pacific region at Ipsen, now leads iRegene's global business development and international strategy.
To accelerate global clinical translation and commercialization, iRegene places great emphasis on the philosophy of 'cooperation and mutual benefit'. At the end of 2021, iRegene entered a long-term collaboration with Danaher Corporation to co-develop next-generation platforms for clinical application. Under this partnership, Danaher will play an active role in developing multi-directional platforms for future iRegene Therapeutics projects. This will involve supplying advanced detection instruments and technical resources relating to life sciences research, the development of effective compounds and screening, multi-omics cell mechanism research, and multi-substance screening. Danaher will help iRegene Therapeutics to enhance the efficiency of platform construction and its ability to deliver practical solutions. Danaher will also support iRegene Therapeutics in developing distinctive, innovative drug pipelines and establishing a research and production base. This strategic cooperation has recently been elevated to the iRegene - Danaher Joint Innovation Center, which is the world's first "Joint Innovation Center for Chemically Induced Therapies and Microphysiology Systems". The center will focus on integrating artificial intelligence (AI)-driven chemically induced cell therapy R&D with microphysiology systems technology. It is committed to accelerating the clinical translation and application of innovative therapies, and providing patients globally with more precise and effective treatment solutions for diseases. Danaher will fully support iRegene Therapeutics' future planning and development, aiming to jointly advance innovative development in China's life sciences research.
iRegene's breakthrough technology platform, strategic advantages and dedicated team have secured continuous support from several leading venture capital firms, with cumulative financing reaching nearly 400 million RMB (55.5 million USD). The company is advancing multiple programs through clinical development, targeting a win-win situation for its products and the capital markets alike, while providing patients around the world with next-generation chemically induced cell therapies that can genuinely reverse disease progression.
About iRegene Therapeutics
iRegene Therapeutics is a biotechnology company committed to becoming a global leader in universal chemical-induced cell therapy. As one of the first companies to harness AI and + chemical induction for the specific functional modification of cells, iRegene offers a safer, more scalable, and cost-effective alternative to traditional gene or cell therapies. Its pipeline targets diseases with high unmet need, including neurodegenerative disorders such as Parkinson's disease and blindness. Through pioneering science, strategic global partnerships, and a visionary leadership team, iRegene is reshaping the future of regenerative medicine - making advanced therapies accessible to patients worldwide.
In August 2023, the NMPA approved the commencement of Phase I clinical trials for iRegene's first product: 'Human Dopaminergic Precursor Cell, NouvNeu001'. This product was developed using the 'AI+ Chem' platform. This made it the world's first chemically induced pluripotent stem cell (iPSC)-derived therapy to enter clinical trials. In June 2024, it was approved by the U.S. FDA for overseas clinical trials. Even more groundbreakingly, in March 2024, iRegene's 'Chemical Induction Platform' became the first system ever to be granted exemption by the FDA. The company's second product, NouvNeu003, which is intended for the treatment of early-onset Parkinson's disease, received NMPA approval in December 2023 and entered Phase I clinical trials. Both NouvNeu001 and NouvNeu003 have now completed Phase I trials. The Phase I results demonstrate good safety, tolerability, and encouraging efficacy in improving motor and non-motor symptoms. The Phase II trial for NouvNeu001 began in April 2025. In parallel, iRegene's first-in-class ophthalmic therapy, was granted Orphan Drug Designation (ODD) by the U.S. FDA in March 2024.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 hours ago
- Globe and Mail
Wynn Resorts Announces $1 Billion Senior Notes Issuance
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Wynn Resorts ( (WYNN)) has shared an announcement. On August 12, 2025, Wynn Macau, a subsidiary of Wynn Resorts, announced a purchase agreement for the issuance of $1 billion in senior notes due in 2034, with an interest rate of 6.750%. The proceeds are intended for general corporate purposes, including debt repayment. The issuance is expected to enhance the company's financial flexibility, although it carries risks such as potential change of control provisions that could require repurchase of the notes. The most recent analyst rating on (WYNN) stock is a Hold with a $114.00 price target. To see the full list of analyst forecasts on Wynn Resorts stock, see the WYNN Stock Forecast page. Spark's Take on WYNN Stock According to Spark, TipRanks' AI Analyst, WYNN is a Neutral. Wynn Resorts' strong operational recovery and strategic financial moves are offset by significant balance sheet risks and valuation concerns. The positive earnings call and corporate events provide a favorable outlook, but financial health remains a critical area for improvement. To see Spark's full report on WYNN stock, click here. More about Wynn Resorts Wynn Resorts is a prominent player in the hospitality and entertainment industry, primarily focusing on luxury casino resorts. The company operates internationally, with significant market presence in Macau and the United States. Average Trading Volume: 2,132,760 Technical Sentiment Signal: Buy Current Market Cap: $11.7B For detailed information about WYNN stock, go to TipRanks' Stock Analysis page. Disclaimer & Disclosure Report an Issue
Globe and Mail
4 hours ago
- Globe and Mail
Tesla's 10X P/S Premium: Is the Stock a Buy, Hold or Sell Now?
Tesla TSLA is one of those stocks whose valuation has long been divorced from its fundamentals. It has always traded at a premium, backed by promises of its long-term potential. For years, that premium felt somewhat justified. Tesla didn't just sell cars — it transformed the electric vehicle (EV) space, much like Amazon reshaped retail and Netflix disrupted entertainment. For many, Tesla was the first name that came to mind when talking about EVs. But that first-mover advantage is fading. Competition is fierce. Tesla's lineup looks dated, with no major launches lately. Meanwhile, legacy automakers, EV startups and especially Chinese rivals are flooding the market with more affordable and increasingly attractive options. Having said that, Tesla has bold ambitions — from robotaxis to full autonomy — and it hopes these will become the next growth engine as EV sales momentum slows. But progress on that front has been slower than expected. So, are there really enough tailwinds to support Tesla's sky-high valuation? The stock trades at more than 10X forward 12-month sales, far above the industry average of 2.68X. At this point, should investors bet on Tesla's long-term vision, or do today's headwinds make it too risky? Let's dig in. TSLA's Weak Q2: Deliveries, Sales, Margins and FCF Slide Tesla's financials continue to weaken, with declining deliveries, revenues, margins and cash flow. After its first-ever annual delivery decline in 2024, 2025 is off to a rough start. Deliveries fell 13% year over year in the first quarter, followed by another 13.4% drop in the second quarter. China's EV giant China's BYD Co Ltd BYDDY continues to challenge Tesla. In the fourth quarter of 2023, BYD briefly took the EV sales crown from Tesla before ending the full year just behind. The same pattern was repeated in 2024. In first-quarter 2025, BYD delivered over 416,000 BEVs, outpacing Tesla's 336,000. In the second quarter, BYD reported 606,993 BEVs sold (up 42.5% year over year), marking its third straight quarter of beating Tesla in battery EV sales. The last reported quarter marked Tesla's sharpest quarterly revenue decline in more than a decade, raising questions not only about demand but also about the company's brand image amid Elon Musk's increasingly polarizing political activity. Automotive revenues, Tesla's largest contributor, led the slide due to fewer deliveries and lower average selling prices. Model 3/Y deliveries fell 11.5%, while higher-end models (Model X/S) plunged roughly 52%, highlighting soft demand across the lineup. Profitability also came under pressure. Automotive gross margin contracted to 17%, down 100 basis points from last year. Operating margin shrank to just 4.1%, a steep 220 basis point drop. Notably, while operating expenses fell only 1%, revenues contracted 12%, underscoring weaker efficiency. Earnings and cash generation mirrored this trend. EPS fell 23% year over year, while operating cash flow dropped 30%. With capex up 5%, free cash flow tumbled 89% to just $146 million — its third straight quarterly slide. Musk has already warned of 'rough quarters' ahead, and second-quarter results show exactly why investors should take him at his word. Are TSLA's FSD & Robotaxi Progress Enough? Even as Tesla's financials show strain, the company continues to push hard on autonomy. Growing adoption of Full Self-Driving (FSD) and the launch of a paid robotaxi service are being pitched as the next chapter of growth — but the road ahead is far from smooth. Musk expects FSD software to secure regulatory approval in parts of Europe by year-end, though this target was already delayed from his earlier March projection. Despite its branding, FSD is still a driver-assistance system that requires human supervision, making full autonomy a work in progress. Meanwhile, Tesla officially rolled out its robotaxi service in Austin in June — a milestone in its self-driving ambitions. The company plans to expand into major U.S. markets such as the Bay Area, Nevada, Arizona and Florida, pending approvals. Robotaxis in Austin have already logged more than 7,000 miles without safety-critical interventions, and Tesla expects to scale service areas more than tenfold. Musk suggested that 'probably half the U.S. population' could have access to robotaxis by year-end, assuming regulators agree. Still, Tesla is hardly the leader here. Alphabet 's GOOGL Waymo dominates the U.S. robotaxi market, running commercial services in four cities and delivering over 250,000 paid rides per week. Backed by a $5 billion multi-year investment by Alphabet, Waymo has years of real-world testing, strong partnerships and a head start that Tesla must catch up to. What Do Tesla's Estimates Say? The Zacks Consensus Estimate for Tesla's 2025 revenues and EPS implies a 6% and 31.4% decline, respectively, on a year-over-year basis. Estimates for EPS have also been trending south over the past 60 days. Conclusion Tesla isn't being priced like a carmaker with falling sales and shrinking margins — it's still being valued like a tech giant of the future. That mismatch is the problem. Robotaxis and FSD may one day add value, but right now, they are promises against a backdrop of deteriorating fundamentals and intensifying competition. The execution remains uncertain and rivals like BYD and Alphabet's Waymo are already pulling ahead in their respective markets. At over 10X forward sales, Tesla's valuation leaves no margin for error. With estimates moving lower, cash flow drying up and rivals taking share, the risks far outweigh the potential rewards in the near term. Tesla no longer commands its premium. Until the company proves it can reignite growth or deliver meaningful progress on autonomy, investors may find better opportunities elsewhere in the auto and tech space. Tesla currently carries a Zacks Rank #4 (Sell) and looks like a stock to avoid rather than chase. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. See our %%CTA_TEXT%% report – free today! 7 Best Stocks for the Next 30 Days Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tesla, Inc. (TSLA): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report Byd Co., Ltd. (BYDDY): Free Stock Analysis Report
Cision Canada
4 hours ago
- Cision Canada
Landis+Gyr Recognized by Frost & Sullivan as the 2025 Global Company of the Year for Excellence in Advanced Metering Infrastructure
The company is recognized for visionary innovation and customer impact in redefining metering infrastructure and enabling grid modernization through intelligent, real-time solutions. SAN ANTONIO, Aug. 19, 2025 /CNW/ -- Frost & Sullivan is pleased to recognize Landis+Gyr as the 2025 Global Company of the Year in the Advanced Metering Infrastructure (AMI) sector for its outstanding achievements in visionary innovation and in customer impact. This distinction highlights Landis+Gyr's consistent leadership in driving measurable outcomes, strengthening its market position, and delivering customer-centric innovation, marking the company's ninth recognition by Frost & Sullivan in the AMI space since 2013. Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: visionary innovation and customer impact. Landis+Gyr excels in both, demonstrating its ability to align strategic initiatives with market demand while executing them efficiently, consistently, and at scale. "By transforming each endpoint into a real-time intelligence node, Landis+Gyr bridges the gap between a utility's physical infrastructure and its digital data systems—enabling not just visibility into what is happening at the grid edge, but also deep insight into why it is happening. This unified digital-physical grid architecture effectively addresses a long-standing blind spot in grid management—achieving comprehensive situational awareness from edge to enterprise," said Gautham Gnanajothi, global vice president of research at Frost & Sullivan. Guided by a long-term growth strategy focused on metering infrastructure modernization, digitalization, and utility partnerships, Landis+Gyr has shown its ability to adapt and lead in a rapidly evolving landscape. The company's strategic agility and sustained investment in grid intelligence and real-time data capabilities have enabled it to scale effectively across the globe. Innovation remains central to Landis+Gyr's approach. Its suite of solutions addresses the full spectrum of utility metering and grid modernization needs, offering flexibility, interoperability, and enhanced performance across electricity, gas, and water infrastructure. "We're honored to be recognized by Frost & Sullivan for our continued leadership in AMI," said Peter Mainz, CEO of Landis+Gyr. "This award reflects the dedication of our global team and our commitment to innovation at the grid edge, where real-time intelligence is transforming how energy is managed. We're not standing still. Through ongoing investment in cutting-edge technologies and customer-centric solutions, we're shaping a smarter, more resilient energy future." Landis+Gyr's unwavering commitment to customer experience further strengthens its market position. By streamlining service delivery, enabling utilities with near real-time data through its managed services, and maintaining high levels of system reliability, the company continues to meet the evolving needs of its global customer base. Its partner-led delivery model and focus on localization have been key to delivering long-term value across diverse regulatory and market environments. Frost & Sullivan commends Landis+Gyr for setting a high standard in competitive strategy, execution, and market responsiveness. The company's vision, innovation pipeline, and customer-first culture are shaping the future of advanced metering infrastructure and driving tangible results at scale. Each year, Frost & Sullivan recognizes a Company of the Year in various sectors to highlight those that demonstrate outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. This recognition honors forward-thinking organizations that are reshaping their industries through innovation and growth excellence. Frost & Sullivan Best Practices recognitions celebrate companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact: Ashley Shreve E: [email protected] About Landis+Gyr Landis+Gyr is a leading global provider of integrated energy management solutions. We measure and analyze energy utilization to generate empowering analytics for smart grid and infrastructure management, enabling utilities and consumers to reduce energy consumption. Our innovative and proven portfolio of software, services and intelligent sensor technology is a key driver to decarbonize the grid. Having enabled 9 million tons of CO2 savings in FY 2024 through our product offerings, Landis+Gyr manages energy better – since 1896. With sales of USD 1.7 billion in FY 2024, Landis+Gyr employs around 6,300 talented people across five continents. For more information, please visit our website: Contact: E:
